Targeted modification of rat genome

Patent metadata

Field	Value
Publication number	US-10975390-B2
Application number	US-201916451859-A
Country	US
Kind code	B2
Filing date	Jun 25, 2019
Priority date	Apr 16, 2013
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.

First claim

We claim:

1. A method for making a genetically modified rat pluripotent stem cell clone capable of generating a genetically modified rat comprising a targeted genetic modification and transmitting the targeted genetic modification through the germline, comprising:
(a) culturing a population of rat pluripotent stem cells on a layer of feeder cells that is not modified to express leukemia inhibitory factor (LIF) with a medium comprising about 50 U/mL to about 150 U/mL LIF, N2 supplement, B27 supplement, and a combination of inhibitors consisting of MEK inhibitor PD0325901 and GSK3 inhibitor CHIR99021;
(b) introducing into the rat pluripotent stem cells a large targeting vector (LTVEC) comprising an insert nucleic acid flanked by a 5′ homology arm homologous to a first nucleic acid sequence at a genomic locus of interest and a 3′ homology arm homologous to a second nucleic acid sequence at the genomic locus of interest to produce the targeted genetic modification via homologous recombination, wherein the sum total of the 5′ and the 3′ homology arms is at least 10 kb; and
(c) obtaining a rat pluripotent stem cell clone comprising the targeted genetic modification at the genomic locus of interest, wherein the obtaining consists of identifying in a single cloning step a rat pluripotent stem cell clone comprising the targeted genetic modification at the genomic locus of interest and capable of generating a genetically modified rat comprising the targeted genetic modification and transmitting the targeted genetic modification through the germline.

2. The method of claim 1 , wherein the rat pluripotent stem cells in step (a) are rat embryonic stem (ES) cells.

3. The method of claim 2 , wherein the rat ES cells are male (XY) rat ES cells or female (XX) rat ES cells.

4. The method of claim 2 , wherein the rat ES cells are diploid and/or form spherical, free-floating colonies in culture.

5. The method of claim 1 , wherein the rat pluripotent stem cells in step (a) are derived from a DA strain or an ACI strain.

6. The method of claim 1 , wherein the rat pluripotent stem cells in step (a) are characterized by one or more of the following characteristics:
(I) expression of at least one pluripotency marker selected from the group consisting of Dnmt3L, Eras, Err-beta, Fbxo15, Fgf4, Gdf3, Klf4, Lef1, LIF receptor, Lin28, Nanog, Oct4, Sox15, Sox2, and Utf1;
(II) lack of expression of one or more of the pluripotency markers c-Myc, Ecat1, and Rexo1;
(III) lack of expression of one or more of the mesodermal markers Brachyury and Bmpr2;
(IV) lack of expression of one or more of the endodermal markers Gata6, Sox17, and Sox7; and
(V) lack of expression of one or more of the neural markers Nestin and Pax6.

7. The method of claim 1 , wherein the medium comprises about 75 U/mL to about 125 U/mL LIF.

8. The method of claim 7 , wherein the medium comprises about 90 U/mL to about 110 U/mL LIF.

9. The method of claim 8 , wherein the medium comprises about 100 U/mL LIF.

10. The method of claim 1 , wherein the LIF is a mouse LIF.

11. The method of claim 1 , wherein the concentration of MEK inhibitor PD0325901 is 0.8 μM to about 1.2 μM, and the concentration of GSK3 inhibitor CHIR99021 is about 2.5 μM to about 3.5 μM.

12. The method of claim 11 , wherein the concentration of MEK inhibitor PD0325901 is about 1 μM, and the concentration of GSK3 inhibitor CHIR99021 is about 3 μM.

13. The method of claim 9 , wherein the concentration of the MEK inhibitor PD0325901 is about 1 μM, and the concentration of GSK3 inhibitor CHIR99021 is about 3 μM.

14. The method of claim 1 , wherein the feeder cells comprise mitotically inactivated mouse embryonic fibroblasts.

15. The method of claim 1 , wherein the feeder cells comprise mitotically inactivated mouse embryonic fibroblasts, and the medium is a 2i medium comprising DMEM/F12 basal medium at a concentration of 1×; neurobasal medium at a concentration of 1×; penicillin/streptomycin at a concentration of 1%; L-Glutamine at a concentration of 4 mM; 2-mercaptoethanol at a concentration of 0.1 mM; N2 supplement at a concentration of 1×; B27 supplement at a concentration 1×; LIF at a concentration of 100 U/mL; MEK inhibitor PD0325901 at a concentration of 1 μM, and GSK3 inhibitor CHIR99021 at a concentration of 3 μM.

16. The method of claim 1 , wherein:
(I) the sum total of the 5′ and the 3′ homology arms of the LTVEC is from 10 kb to 150 kb,
(II) the 5′ homology arm ranges from 5 kb to 100 kb or the 3′ homology arm ranges from 5 kb to 100 kb; or
(III) the LTVEC is from 20 kb to 400 kb.

17. The method of claim 1 , wherein the insert nucleic acid is from about 5 kb to about 400 kb.

18. The method of claim 1 , wherein the insert nucleic acid:
(i) comprises a polynucleotide of interest comprising a genomic nucleic acid sequence that encodes a human immunoglobulin heavy chain variable region amino acid sequence;
(ii) comprises a polynucleotide of interest comprising a genomic nucleic acid sequence that encodes a human immunoglobulin light chain variable region amino acid sequence;
(iii) comprises a polynucleotide of interest comprising a polynucleotide encoding at least a region of a T cell receptor; or
(iv) comprises a polynucleotide of interest comprising at least one disease allele.

19. The method of claim 18 , wherein the insert nucleic acid comprises a polynucleotide of interest comprising a polynucleotide encoding at least a region of a T cell receptor alpha.

20. The method of claim 1 , wherein the insert nucleic acid:
(i) is from a human;
(ii) comprises a knock-in allele of at least one exon of an endogenous gene;
(iii) comprises a regulatory element;
(iv) comprises a conditional allele;
(v) comprises a nucleic acid flanked by site-specific recombination target sequences;
(vi) comprises a polynucleotide encoding a selection marker; or
(vii) comprises a reporter gene operably linked to a promoter.

21. The method of claim 20 , wherein the insert nucleic acid comprises a polynucleotide encoding a selection marker and/or a reporter gene flanked by site-specific recombination target sequences or comprises a self-deleting selection cassette.

22. The method of claim 1 , wherein introducing step (b) further comprises introducing a nuclease agent or a nucleic acid encoding the nuclease agent, wherein the nuclease agent promotes homologous recombination between the LTVEC and the genomic locus of interest in the rat pluripotent stem cells.

23. The method of claim 22 , wherein the nuclease agent comprises:
(I) a chimeric protein comprising a zinc finger-based DNA binding domain fused to a FokI endonuclease;
(II) a chimeric protein comprising a Transcription Activator-Like Effector Nuclease (TALEN); or
(III) a CRISPR/Cas system.

24. The method of claim 23 , wherein the nuclease agent comprises the CRISPR/Cas system, wherein the CRISPR/Cas system comprises a Cas9 nuclease and a guide RNA.

25. The method of claim 24 , wherein the guide RNA comprises the sequence set forth in SEQ ID NO: 2, 3, 4, 5, 6, 7, or 8.

26. The method of claim 1 , wherein the targeted genetic modification is biallelic.

27. The method of claim 1 , wherein the targeted genetic modification comprises deletion of an endogenous rat nucleic acid sequence, wherein the deletion ranges from about 5 kb to about 3 Mb.

28. The method of claim 1 , wherein the targeted genetic mo

Assignees

• Regeneron Pharma

Inventors

• Lee Jeffrey D
• Mujica Alexander O
• Auerbach Wojtek
• Lai Ka-Man Venus
• Valenzuela David M
• Yancopoulos George D

Classifications

• C12N15/907

  in mammalian cells · CPC title

• C12N15/8509 Primary

  for producing genetically modified animals, e.g. transgenic · CPC title

• A01K67/0276 Primary

  Knock-out vertebrates · CPC title

• A01K67/0278 Primary

  Knock-in vertebrates, e.g. humanised vertebrates · CPC title

• A01K2267/0381

  Animal model for diseases of the hematopoietic system · CPC title